Inhibitors of growth factor activation enzymes

1. A compound of Formula (II):

Y—P 4 —P 3 —P 2 —P 1 —Z  (II)

wherein

Y is acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluorenylmethoxycarbonyl (FMOC), benzyl, or a fluorophore;

P 1 is a residue of an amino acid selected from the group consisting of Arg and D-Arg;

P 2 is a residue of an amino acid selected from the group consisting of Leu and hLeu;

P 3 is a residue of an amino acid selected from the group consisting of Arg, Lys, Trp, Leu, Gln, Phe, His, hArg, D-Trp, His(3-Bom), and L-Phe(NO 2 );

P4 is a residue of an amino acid selected from the group consisting of Arg, Lys, Trp, Ser, Phe, Thr, Asn, His(3-Bom), and D-Trp; and

Z is a

or a benzothiazole of Formula (IV) or (V)

wherein

J 1 is C(O), SO 2 , CH 2 , or heterocyclo;

K 1 is a D- or L-amino acid, wherein the C-terminus is —COOH, —C(O)NH 2 , —OH, —OR 10 , —NH 2 , —NR 11 R 12 , —H, or heterocyclo;

R 10 is C 1 to C 12 alkyl, cycloalkyl, alkylaryl, or aryl;

R 11 and R 12 are each independently H, C 1 to C 12 alkyl, cycloalkyl, alkylaryl, aryl, or heterocyclo; and R 11 and R 12 optionally form a ring; and

L 1 is H, alkyl, cycloalkyl, alkylaryl, benzyl, substituted benzyl, 2- or 3- or 4-piperdinyl, 2- or 3- or 4-pyridinyl, aryl, heterocyclo, or heteroaryl.

2. The compound of claim 1 wherein Y is acetyl and/or Z is

3. The compound of claim 1 wherein P 1 is an amino acid residue of Arg; P 2 is an amino acid residue of Leu; P 3 is an amino acid residue of His, Gln, Arg, Lys, Leu, Phe, or Trp; and P 4 is an amino acid residue of Ser, Lys, Phe, Trp, or His(3-Bom).

4. The compound of claim 2 wherein P 1 is an amino acid residue of Arg; P 2 is an amino acid residue of Leu; P 3 is an amino acid residue of Arg, Leu, Trp, Phe, His, Gln, or Lys; and P 4 is an amino acid residue of Phe, Trp, Ser, Lys, or His(3-Bom).

5. The compound claim 1 wherein P 1 is an amino acid residue of Arg; P 2 is an amino acid residue of Leu; P 3 is an amino acid residue of Leu, Trp, Phe, His, Gln, or Lys; and P 4 is an amino acid residue of Phe, Lys, or His(3-Bom).

6. The compound of claim 1 wherein P 4 -P 3 -P 2 -P 1 of Formula (II) is a tetrapeptide selected from the group consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 5, SEQ ID NO 6, SEQ ID NO 7, SEQ ID NO 8, SEQ ID NO 9, SEQ ID NO 10, SEQ ID NO 11, SEQ ID NO 12, SEQ ID NO 14, SEQ ID NO 15, SEQ ID NO 16, SEQ ID NO 17, and SEQ ID NO 18.

7. The compound of claim 1 wherein Z is a benzothiazole of Formula (IV) or Formula (V).

8. The compound of claim 1 wherein L 1 is a substituted benzyl group.

9. The compound of claim 2 wherein Z is

10. The compound of claim 6 wherein Y is acetyl and Z is a

11. The compound of claim 1 , wherein the compound is selected from the group consisting of:

12. A method of inhibiting tumor progression comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 .

13. A method of treating a cancer in a subject comprising administering to the subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 .

14. The method of claim 13 , wherein the cancer is selected from the group consisting of breast, ovarian, prostate, endometrial, colon, pancreatic, head and neck, gastric, renal, brain, liver, bladder, kidney, lung, esophageal, leukemias, multiple myeloma, lymphoma, and melanoma.

15. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1 .

16. A fluorescent imaging composition comprising a compound of Formula (II) of claim 1 and a fluorophore selected from the group consisting of Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and Cy7.5.

17. A method of detecting imaging cancer comprising:

administering to a subject the fluorescent imaging composition of claim 16 ;

detecting fluorescence of the fluorescent imaging composition within the body of the subject,

wherein fluorescence of the fluorescent imaging composition indicates the existence of cancer.

18. A radiolabeled imaging composition comprising a compound of Formula (II) of claim 1 and a radioisotope selected from the group consisting of 11 C, 13 N, 15 O, 18 F, 75 Br, 124 I, 125 I, and 131 I.

19. A method of imaging cancer comprising:

administering to a subject the radiolabeled imaging composition of claim 18 ; and

detecting radiation of the radiolabeled imaging composition within the body of the subject,

wherein the radiation of the radiolabeled imaging composition indicates the existence of cancer.

20. The compound of claim 1 wherein Z is a benzothiazole of Formula (IV).

21. The compound of claim 1 wherein P 2 forms a bond with P 4 to form a cyclic peptide.

22. The compound of claim 1 wherein the compound has the following formula:

wherein

Y is acetyl;

P 2 is a residue of an amino acid selected from the group consisting of Leu and hLeu;

P 3 is a residue of an amino acid selected from the group consisting of Arg, Lys, Trp, Leu, Gln, Phe, His, His(3-Bom), and L-Phe(NO 2 );

P 4 is a residue of an amino acid selected from the group consisting of Arg, Lys, Trp, Ser, Phe, His(3-Bom); and

Z is

wherein

J 1 is C(O), SO 2 , CH 2 , or heterocyclo,

K 1 is a D- or L-amino acid, wherein the C-terminus is —COOH, —C(O)NH 2 , —OH, —OR 10 , —NH 2 , —NR 11 R 12 , —H, or heterocyclo;

R 10 is C 1 to C 12 alkyl, cycloalkyl, alkylaryl, or aryl;

R 11 and R 12 are each independently H, C 1 to C 12 alkyl, cycloalkyl, alkylaryl, aryl, or heterocyclo; and R 11 and R 12 optionally form a ring; and

L 1 is H, alkyl, cycloalkyl, alkylaryl, benzyl, substituted benzyl, 2- or 3- or 4-piperdinyl, 2- or 3- or 4-pyridinyl, aryl, heterocyclo, or heteroaryl.

23. A compound of Formula (II):

Y—P 4 —P 3 —P 2 —P 1 —Z  (II)

wherein

Y is acetyl, tert-butyloxycarbonyl, benzyloxymethyl acetyl, carboxybenzyl, fluorenylmethoxycarbonyl (FMOC), benzyl, or a fluorophore;

P 1 is a residue of Arg;

P 2 is a residue of an amino acid selected from the group consisting of Leu or hLeu;

P 3 is a residue of an amino acid selected from the group consisting of Gln, Agp, Nle(O-Bzl), Orn, Met(O), Arg, hArg, Trp, hCha, hTyr, hPhe, and Lys;

P 4 is a residue of an amino acid selected from the group consisting of Agp, DAB(Z), Nle(O-Bzl), Orn, Arg(NO 2 ), Arg, Lys, L-Arg(Z)2, L-Glu(Bzl), His(3-Bom), Lys(2-Cl—Z), dhLeu, Idc, Chg, dhAbu, and L-hArg; and

Z is

wherein

J 1 is C(O), SO 2 , CH 2 , or heterocyclo;

K 1 is a D- or L-amino acid, wherein the C-terminus is —COOH, —C(O)NH 2 , —OH, —OR 10 , —NH 2 , —NR 11 R 12 , —H, or heterocyclo;

R 10 is C 1 to C 12 alkyl, cycloalkyl, alkylaryl, or aryl;

R 11 and Ria are each independently H, C 1 to C 12 alkyl, cycloalkyl, alkylaryl, aryl, or heterocyclo; and R 11 and R 12 optionally form a ring; and

L 1 is H, alkyl, cycloalkyl, alkylaryl, benzyl, substituted benzyl, 2- or 3- or 4-piperdinyl, 2- or 3- or 4-pyridinyl, aryl, heterocyclo, or heteroaryl.